Literature DB >> 11255427

Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.

M H Stoler1, M Schiffman.   

Abstract

CONTEXT: Despite a critical presumption of reliability, standards of interpathologist agreement have not been well defined for interpretation of cervical pathology specimens.
OBJECTIVE: To determine the reproducibility of cytologic, colposcopic histologic, and loop electrosurgical excision procedure (LEEP) histologic cervical specimen interpretations among multiple well-trained observers. DESIGN AND
SETTING: The Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion (ASCUS-LSIL) Triage Study (ALTS), an ongoing US multicenter clinical trial.
SUBJECTS: From women enrolled in ALTS during 1996-1998, 4948 monolayer cytologic slides, 2237 colposcopic biopsies, and 535 LEEP specimens were interpreted by 7 clinical center and 4 Pathology Quality Control Group (QC) pathologists. MAIN OUTCOME MEASURES: kappa Values calculated for comparison of the original clinical center interpretation and the first QC reviewer's masked interpretation of specimens.
RESULTS: For all 3 specimen types, the clinical center pathologists rendered significantly more severe interpretations than did reviewing QC pathologists. The reproducibility of monolayer cytologic interpretations was moderate (kappa = 0.46; 95% confidence interval [CI], 0.44-0.48) and equivalent to the reproducibility of punch biopsy histopathologic interpretations (kappa = 0.46; 95% CI, 0.43-0.49) and LEEP histopathologic interpretations (kappa = 0.49; 95% CI, 0.44-0.55). The lack of reproducibility of histopathology was most evident for less severe interpretations.
CONCLUSIONS: Interpretive variability is substantial for all types of cervical specimens. Histopathology of cervical biopsies is not more reproducible than monolayer cytology, and even the interpretation of LEEP results is variable. Given the degree of irreproducibility that exists among well-trained pathologists, realistic performance expectations should guide use of their interpretations.

Entities:  

Mesh:

Year:  2001        PMID: 11255427     DOI: 10.1001/jama.285.11.1500

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  194 in total

1.  Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible.

Authors:  Philip E Castle; Attila T Lorincz; Iwona Mielzynska-Lohnas; David R Scott; Andrew G Glass; Mark E Sherman; John E Schussler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

2.  Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer.

Authors:  Johannes Schweizer; Peter S Lu; Charles W Mahoney; Marthe Berard-Bergery; Minh Ho; Valli Ramasamy; Jon E Silver; Arnima Bisht; Yassine Labiad; Roger B Peck; Jeanette Lim; Jose Jeronimo; Roslyn Howard; Patti E Gravitt; Philip E Castle
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

3.  Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.

Authors:  Nancy E Joste; Brigitte M Ronnett; William C Hunt; Amanda Pearse; Erika Langsfeld; Thomas Leete; MaryAnn Jaramillo; Mark H Stoler; Philip E Castle; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-02       Impact factor: 4.254

4.  Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice.

Authors:  Walter Kinney; Barbara Fetterman; J Thomas Cox; Thomas Lorey; Tracy Flanagan; Philip E Castle
Journal:  Gynecol Oncol       Date:  2011-01-26       Impact factor: 5.482

5.  Single point vs. mapping approach for spectral cytopathology (SCP).

Authors:  Jennifer M Schubert; Antonella I Mazur; Benjamin Bird; Milos Miljković; Max Diem
Journal:  J Biophotonics       Date:  2010-08       Impact factor: 3.207

6.  Screening: HPV testing for cervical cancer: the good, the bad, and the ugly.

Authors:  Philip E Castle
Journal:  Nat Rev Clin Oncol       Date:  2010-07       Impact factor: 66.675

7.  MOLECULAR MARKERS OF EARLY CERVICAL NEOPLASIA.

Authors:  Alvaro P Pinto; Christopher P Crum; Michelle S Hirsch
Journal:  Diagn Histopathol (Oxf)       Date:  2010-10-01

8.  A Comparison of the Natural History of HPV Infection and Cervical Abnormalities among HIV-Positive and HIV-Negative Women in Senegal, Africa.

Authors:  Hilary K Whitham; Stephen E Hawes; Haitao Chu; J Michael Oakes; Alan R Lifson; Nancy B Kiviat; Papa Salif Sow; Geoffrey S Gottlieb; Selly Ba; Marie P Sy; Shalini L Kulasingam
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-17       Impact factor: 4.254

9.  Individual and partner risk factors associated with abnormal cervical cytology among women in HIV-discordant relationships.

Authors:  Jason Soh; Anne F Rositch; Laura Koutsky; Brandon L Guthrie; Robert Y Choi; Rose K Bosire; Ann Gatuguta; Jennifer S Smith; James Kiarie; Barbara Lohman-Payne; Carey Farquhar
Journal:  Int J STD AIDS       Date:  2013-09-18       Impact factor: 1.359

10.  Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2.

Authors:  Mark Schiffman; Kai Yu; Rosemary Zuna; S Terence Dunn; Han Zhang; Joan Walker; Michael Gold; Noorie Hyun; Greg Rydzak; Hormuzd A Katki; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2016-10-17       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.